Glimepiride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.25-1 mg/kg	q24h	Duration: Long-term, adjust based on glucose monitoring Notes: Start at low end and titrate based on blood glucose curves. Not a substitute for insulin in insulin-dependent diabetes.
Cat	PO	0.25-0.5 mg/kg	q24h	Duration: Long-term, adjust based on glucose monitoring Notes: May be used in diabetic remission protocols. Monitor for hypoglycemia.
Horse	PO	Not established	Not established	Duration: Not established Notes: Not recommended due to lack of efficacy and safety data.
Cattle	PO	Not established	Not established	Duration: Not established Notes: Not indicated.
Small Ruminants	PO	Not established	Not established	Duration: Not established Notes: Not indicated.
Rabbit	PO	Not established	Not established	Duration: Not established Notes: Not commonly used.
Bird/Poultry	PO	Not established	Not established	Duration: Not established Notes: Not indicated.
Exotic/Other	PO	Not established	Not established	Duration: Not established Notes: Use with caution, limited data.

Clinical Indications & Species Uses

General Indications

Treatment of hyperglycemia in animals with type 2 diabetes mellitus or insulin resistance where residual pancreatic beta-cell function exists.

Dog (Canine)

Diabetes mellitus (non-insulin-dependent or type 2) in dogs, though insulin is the primary treatment; glimepiride may be used as an adjunct or in cases of residual pancreatic function.

Cat (Feline)

Diabetes mellitus in cats, particularly when there is some residual beta-cell function; often used as an alternative to insulin in early or mild cases.

Pharmacology & Mechanism of Action

Drug Class: Sulfonylurea | Pharmacological Group: Antidiabetic agent

Mechanism of Action: Glimepiride primarily stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium (K-ATP) channel. This binding closes the channel, leading to cell membrane depolarization, opening of voltage-gated calcium channels, and subsequent influx of calcium, which triggers exocytosis of insulin-containing granules. Additionally, glimepiride may have extrapancreatic effects, including increasing insulin sensitivity in peripheral tissues and reducing hepatic glucose production. It also has a lower affinity for cardiac and vascular K-ATP channels compared to other sulfonylureas, potentially reducing cardiovascular adverse effects.

Pharmacodynamics: Glimepiride lowers blood glucose by stimulating insulin secretion in a glucose-dependent manner, meaning that its effect is more pronounced when glucose levels are elevated. It also enhances insulin-mediated glucose uptake in muscle and adipose tissue and suppresses hepatic gluconeogenesis. The drug has a rapid onset of action and a prolonged duration of effect, allowing for once-daily dosing. In veterinary patients, the pharmacodynamic response may vary with species and underlying pancreatic function.

⚡ Pharmacokinetics Summary

Absorption: Glimepiride is well absorbed after oral administration, with peak plasma concentrations occurring within 2-3 hours in humans. In dogs, absorption is rapid and nearly complete. Food may slightly delay absorption but does not significantly affect overall bioavailability.

Distribution: Glimepiride is extensively bound to plasma proteins (greater than 99%), primarily to albumin. It distributes into tissues, with a volume of distribution of approximately 8.8 L in humans. In animals, distribution is likely similar, but specific data are limited.

Metabolism: Glimepiride is extensively metabolized in the liver via oxidative biotransformation, primarily by CYP2C9, to two major metabolites: the hydroxy derivative (M1) and the carboxy derivative (M2). M1 has about one-third of the pharmacological activity of the parent drug, while M2 is inactive. In animals, similar metabolic pathways are presumed, but species differences may exist.

Excretion: Glimepiride and its metabolites are excreted primarily in urine (approximately 60%) and feces (approximately 40%). In humans, the elimination half-life is about 5-9 hours, but in animals, it may be shorter. In dogs, the half-life is approximately 2-3 hours, while in cats it may be longer due to slower metabolism.

Half-Life: Dog: 2-3 hours; Cat: approximately 5-8 hours (estimated); Horse: not well documented; Cattle: not well documented.

Bioavailability: Oral bioavailability is nearly complete (approximately 100%) in humans and dogs, with minimal first-pass effect.

Protein Binding: Greater than 99% bound to plasma proteins, primarily albumin.

Available Formulations & Strengths

Oral Tablet 1 mg, 2 mg, 4 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to glimepiride or other sulfonylureas
Diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (requires insulin)
Severe hepatic or renal impairment
Pregnancy and lactation (safety not established in veterinary species)
Type 1 diabetes mellitus (insulin-dependent) in animals

Warnings & Clinical Precautions:

Use with caution in animals with hepatic or renal disease, as drug metabolism and excretion may be impaired.
Monitor blood glucose regularly to adjust dosage and avoid hypoglycemia.
May cause hypoglycemia, especially in animals with reduced food intake or increased exercise.
Not effective in animals with little or no residual pancreatic beta-cell function.
In cats, may be used as part of a comprehensive diabetes management plan including diet and weight control.
Avoid use in animals with a history of sulfonamide allergy (cross-reactivity possible).
Use with caution in debilitated or geriatric animals.

Adverse Effects & Reactions

Common:

Hypoglycemia
Gastrointestinal upset (vomiting, diarrhea)
Decreased appetite

Serious / Severe:

Severe hypoglycemia leading to seizures or coma
Hepatotoxicity (rare)
Blood dyscrasias (leukopenia, thrombocytopenia)

Rare:

Allergic skin reactions
Cholestatic jaundice
Disulfiram-like reaction with alcohol (not relevant in animals)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Beta-blockers	May mask signs of hypoglycemia and impair glucose counter-regulation.	Moderate
Corticosteroids	May increase blood glucose, reducing the efficacy of glimepiride.	Moderate
NSAIDs (e.g., aspirin, phenylbutazone)	May potentiate the hypoglycemic effect by displacing glimepiride from protein binding or reducing renal excretion.	Moderate
Warfarin	Potential for increased anticoagulant effect; monitor coagulation parameters.	Moderate
Sulfonamides	May enhance hypoglycemic effect.	Mild
Insulin	Additive hypoglycemic effect; dose adjustment may be needed.	High

Overdose & Toxicity Management

Signs of Toxicity:

Hypoglycemia (weakness, lethargy, ataxia, tremors, seizures, coma)
Gastrointestinal signs (vomiting, diarrhea)
Hypothermia

Emergency Treatment Protocol: Administer glucose orally or intravenously (e.g., dextrose 50% diluted, or oral glucose gel). Monitor blood glucose closely for 24-48 hours. In severe cases, provide supportive care including intravenous fluids and hospitalization. Consider octreotide or diazoxide in refractory cases, but these are rarely used in veterinary medicine.

Food Animal Withdrawal Times

Not approved for use in food animals; no withdrawal times established. Use in food animals is prohibited or extra-label with strict adherence to regulations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C) in a tight, light-resistant container.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from moisture and light. Keep out of reach of children and animals.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: In the US, glimepiride is not FDA-approved for veterinary use; its use in animals is extra-label. Under AMDUCA, extra-label use is permitted only by or on the order of a veterinarian within a valid VCPR, and only for non-food animals or with extended withdrawal times for food animals. It is not permitted in feed.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Glimepiride is a second-generation sulfonylurea that may be considered for the management of diabetes mellitus in dogs and cats, particularly when there is evidence of residual pancreatic beta-cell function. However, insulin remains the cornerstone of therapy for most diabetic dogs and cats. In cats, glimepiride may be used in early diabetes or during remission induction, but response is variable. It is essential to monitor blood glucose curves and adjust dosing accordingly. Hypoglycemia is the most significant adverse effect, and owners must be educated on recognizing and managing it. Glimepiride should not be used in animals with ketoacidosis or severe concurrent illness. Due to lack of safety and efficacy data, it is not recommended for use in horses, food animals, or exotic species.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)